Compare Incyte Corporation (INCY) vs iShares MSCI India ETF (INDA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs iShares MSCI India ETF — how do they compare? Incyte Corporation trades at $112.77 (market cap $22.85B), while iShares MSCI India ETF trades at $46.03 (market cap $5.73B). The key difference: Incyte Corporation is far larger — about 4× iShares MSCI India ETF's market cap, and Incyte Corporation is trading nearer its 52-week high, iShares MSCI India ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and iShares MSCI India ETF for 58 Days on average.
| INCY | INDA | |
|---|---|---|
Market Cap | $22.85B | $5.73B |
Volume | 1,927,029 | 6,797,522 |
Sector | Health | Broad Market / Factor |
52-Week High | $129.93 | $55.29 |
52-Week Low | $83.80 | $45.42 |
Typical Hold Time | 33 Days | 58 Days |
Enterprise Value | $18.35B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $113.61, up 0.15% on the day, with a mixed technical signal leaning bearish. The company reported strong 2025 results with revenue of $5.14B and net income of $1.29B, and recent earnings beats in Q1 and Q2 2026. Key developments include FDA approval for Atebrioz and a strategic focus on post-JAKAFI growth targeting $4B in non-JAKAFI sales by 2029.
The outlook is cautiously optimistic, supported by robust profitability and pipeline progress, but tempered by near-term earnings pressure and technical weakness. Risks include JAKAFI's patent expiration after 2029 and competitive threats. Analysts maintain a Buy consensus with a $132.43 price target, implying significant upside from current levels.
INDA trades at $45.98, down 0.3% with bearish technical signals showing 19 sell indicators versus 5 buy signals. The ETF faces headwinds from India's economic challenges including coal power shortages, monsoon concerns, and pharma sector export issues. Technical indicators show oversold conditions with RSI readings below 16, suggesting potential for near-term bounce despite the dominant bearish trend.
The outlook remains cautious as India's market composition with heavy banking sector exposure and external pressures from US tariff tensions create uncertainty. Key support at $45 provides critical technical level, while sector-specific challenges in technology and pharmaceuticals warrant careful monitoring of India's economic resilience.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About iShares MSCI India ETF
INDA tracks the MSCI India Index, providing broad exposure to large and mid-cap companies in the Indian stock market. It is structurally dominated by the financials, information technology, and energy sectors, serving as a core instrument for investors seeking a single-country view of India's long-term economic growth.
Read more on INDA →
